Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
The Medicines Discovery Catapult will conduct an in vivo 18F imaging and toxicity study in naive and cancer xenograft bearing mice of our HER2 targeting apoferritin anti-cancer drug delivery platform.
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| MEDICINES DISCOVERY CATAPULT SERVICES LIMITED | 10305216 | £76,536 | - |
Government spending data: This supplier has received £109,853,924 in 37 payments (over £25k) from Department of Health and Social Care, UK Health Security Agency (2021-02-01 to 2022-05-13). View full payment history →